HLS Therapeutics (TSE:HLS) Trading Down 1.1% – Here’s Why

HLS Therapeutics Inc. (TSE:HLS)’s share price fell 1.1% on Wednesday . The company traded as low as C$4.56 and last traded at C$4.65. 4,700 shares were traded during trading, a decline of 17% from the average session volume of 5,639 shares. The stock had previously closed at C$4.70.

HLS Therapeutics Trading Down 1.1%

The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50. The company has a market cap of C$145.42 million, a PE ratio of -10.33 and a beta of 0.49. The company has a fifty day simple moving average of C$4.83 and a two-hundred day simple moving average of C$5.15.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative return on equity of 25.27% and a negative net margin of 38.70%.The firm had revenue of C$18.81 million during the quarter. Analysts anticipate that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.